Autres langues Cardiol Therapeutics Inc.

Actions

CRDL

CA14161Y2006

Recherche biotechnologique et médicale

Temps Différé Toronto S.E. Autres places de cotation 19:04:13 06/07/2026			Varia. 5j.	Varia. 1 janv.
1,555 ^CAD	+1,63%		+4,36%	+18,70%

11/05	Cardiol Therapeutics Inc. publie ses résultats pour le premier trimestre clos le 31 mars 2026	CI
07/05	Cardiol Therapeutics Inc annonce l'acceptation des résultats de phase II Maveric pour publication dans le Journal of the American Heart Association	CI

Autres langues

25/06	Cardiol Therapeutics Reports Results of 2026 Annual General Meeting of Shareholders
25/06	Cardiol Therapeutics Reports Results of 2026 Annual General Meeting of Shareholders
23/06	Cardiol Therapeutics to Webcast Virtual Annual General Meeting of Shareholders on June 24th at 4:30 p.m. EDT
23/06	Cardiol Therapeutics to Webcast Virtual Annual General Meeting of Shareholders on June 24th at 4:30 p.m. EDT
14/05	Cardiol Therapeutics to Participate in Fireside Chat at H.C. Wainwright 4th Annual BioConnect Investor Conference at the NASDAQ
14/05	Cardiol Therapeutics to Participate in Fireside Chat at H.C. Wainwright 4th Annual BioConnect Investor Conference at the NASDAQ
11/05	Cardiol Therapeutics Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026
07/05	Cardiol Adds Results "Further Validate" Ongoing Phase III Trial, Which Recently Surpassed 75% Enrollment
07/05	Cardiol Says Results Demonstrate CardiolRx "May Represent a Paradigm Shift" In the Treatment of Patients With Recurrent Pericarditis
07/05	Cardiol Therapeutics Says Its Phase II MAvERIC Results Accepted For Publication In The Journal Of The American Heart Association
07/05	Cardiol Therapeutics' Phase II MAvERIC Results Accepted for Publication in the Journal of the American Heart Association
07/05	Cardiol Therapeutics' Phase II MAvERIC Results Accepted for Publication in the Journal of the American Heart Association
07/05	Cardiol Therapeutics Inc Announces Phase II Maveric Results Accepted for Publication in the Journal of the American Heart Association
28/04	Cardiol Therapeutics Up In US Premarket As Expands Phase 3 Maveric Trial to Include 7 More Clinical Centers in the U.S.
28/04	Cardiol Therapeutics Expands U.S. MAVERIC Phase III Trial Network to Address Growing Interest in the Pivotal Program
28/04	Cardiol Therapeutics Expands U.S. MAVERIC Phase III Trial Network to Address Growing Interest in the Pivotal Program
28/04	Cardiol Therapeutics Inc. Expands Maveric Phase III Trial Network and Provides Clinical Updates on Cardiolrx
14/04	Cardiol Therapeutics to Highlight MAVERIC Phase III Trial and Recently Published ARCHER Results in Live Interview with Barchart
01/04	Cardiol Therapeutics Fiscal 2025 Loss Narrows; Says Now Fully Funded Through Completion of MAVERIC trial
01/04	Cardiol Therapeutics initiated pivotal Phase III Maveric trial of Cardiolrx in recurrent pericarditis
01/04	Cardiol Therapeutics Inc. Provides Update on Strategic Priorities
01/04	Cardiol Therapeutics Announces Year-End 2025 Update on Operations
31/03	Cardiol Therapeutics Inc. Reports Earnings Results for the Full Year Ended December 31, 2025
25/02	Cardiol Therapeutics to Present at TD Cowen 46th Annual Health Care Conference
10/02	Cardiol Therapeutics Inc. Announces the Publication of Results from Its Phase II Archer Study in ESC Heart Failure